Brokerages Set Alphatec Holdings, Inc. (NASDAQ:ATEC) PT at $17.89

Alphatec Holdings, Inc. (NASDAQ:ATEC) has been assigned a consensus recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $17.89.

A number of analysts have weighed in on the stock. StockNews.com raised shares of Alphatec from a “sell” rating to a “hold” rating in a research note on Friday, February 28th. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Alphatec in a research report on Monday, April 14th. Piper Sandler reaffirmed an “overweight” rating and issued a $15.00 target price (up previously from $13.00) on shares of Alphatec in a report on Friday. Needham & Company LLC reissued a “buy” rating and set a $16.00 price target on shares of Alphatec in a research note on Friday. Finally, Barclays upped their price objective on Alphatec from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Wednesday, January 22nd.

Insiders Place Their Bets

In related news, EVP David Sponsel sold 12,946 shares of the company’s stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $10.73, for a total transaction of $138,910.58. Following the sale, the executive vice president now owns 722,128 shares in the company, valued at $7,748,433.44. This represents a 1.76 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Scott Lish sold 27,453 shares of Alphatec stock in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $11.49, for a total value of $315,434.97. Following the completion of the sale, the chief operating officer now owns 867,677 shares of the company’s stock, valued at approximately $9,969,608.73. The trade was a 3.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 185,857 shares of company stock worth $2,105,682. Company insiders own 22.80% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. R Squared Ltd acquired a new position in shares of Alphatec during the fourth quarter valued at about $29,000. Comerica Bank raised its stake in Alphatec by 66.8% during the 4th quarter. Comerica Bank now owns 3,116 shares of the medical technology company’s stock worth $29,000 after buying an additional 1,248 shares during the period. Nisa Investment Advisors LLC boosted its holdings in Alphatec by 973.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company’s stock worth $43,000 after acquiring an additional 4,234 shares in the last quarter. Quarry LP grew its stake in Alphatec by 79.2% in the fourth quarter. Quarry LP now owns 5,374 shares of the medical technology company’s stock valued at $49,000 after acquiring an additional 2,375 shares during the period. Finally, Newton One Investments LLC bought a new stake in shares of Alphatec during the fourth quarter valued at approximately $50,000. 66.35% of the stock is owned by institutional investors.

Alphatec Price Performance

Shares of ATEC stock opened at $11.98 on Friday. The business has a fifty day simple moving average of $10.48 and a 200 day simple moving average of $9.96. The company has a market cap of $1.75 billion, a P/E ratio of -9.36 and a beta of 1.06. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21. Alphatec has a twelve month low of $4.88 and a twelve month high of $13.79.

Alphatec (NASDAQ:ATEC) last posted its earnings results on Thursday, May 1st. The medical technology company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.23). The company had revenue of $169.18 million during the quarter, compared to the consensus estimate of $167.57 million. Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. The firm’s revenue was up 22.2% compared to the same quarter last year. During the same period last year, the company posted ($0.34) EPS. On average, sell-side analysts forecast that Alphatec will post -1.08 EPS for the current fiscal year.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.